Title |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
|
---|---|
Published in |
Breast Cancer Research, April 2014
|
DOI | 10.1186/bcr3642 |
Pubmed ID | |
Authors |
Miguel Martin, Jan C Brase, Lourdes Calvo, Kristin Krappmann, Manuel Ruiz-Borrego, Karin Fisch, Amparo Ruiz, Karsten E Weber, Blanca Munarriz, Christoph Petry, Cesar A Rodriguez, Ralf Kronenwett, Carmen Crespo, Emilio Alba, Eva Carrasco, Maribel Casas, Rosalia Caballero, Alvaro Rodriguez-Lescure |
Abstract |
EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of distant recurrence in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) patients treated with adjuvant endocrine therapy. Here, we report the prospective-retrospective clinical validation of EP in node-positive chemotherapy-treated ER+/HER2- BC patients from the GEICAM/9906 trial. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
Unknown | 157 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 30 | 19% |
Other | 17 | 11% |
Student > Master | 17 | 11% |
Student > Bachelor | 16 | 10% |
Student > Ph. D. Student | 11 | 7% |
Other | 33 | 21% |
Unknown | 34 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 60 | 38% |
Agricultural and Biological Sciences | 17 | 11% |
Biochemistry, Genetics and Molecular Biology | 11 | 7% |
Psychology | 6 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
Other | 16 | 10% |
Unknown | 43 | 27% |